subject: Xnpt, Actg, And Pwrm.ob Stock Report From Pennytobuck.com [print this page] Power3 Medical Products, IncPower3 Medical Products, Inc. (OTCBB: PWRM) announced recently that, in collaboration with Lourdes R. Bosquez, MD, it has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro protein biomarkers in the blood of untreated Alzheimers disease patients compared to patients treated with the widely used anti-dementia drugs Aricept (Donepezil HCl, Pfizer NYSE: PFE), Exelon (Rivastigmine, Novartis NYSE: NVS), and Namenda (Memantine HCl, Forest Laboratories NYSE: FRX). These results relate to the genetically distinct groups of Alzheimers disease patients, i.e., those individuals who possess the Alzheimers high-risk gene for Apolipoprotein E4 and those who do not possess the gene.
PWRM.ob has filed for patent protection for these findings and will be publishing these seminal results in the near future in one of the worlds most prestigious peer-reviewed scientific journals. PWRM.ob also plans to demonstrate the clinical application and benefits of its NuroPro diagnostic tests to healthcare providers located throughout the world. Power3 believes that this will assist the company greatly in an effort to generate sales of its NuroPro diagnostic tests. PWRM.ob is currently working on a joint distribution effort with a number of potential business partners, such as the companies mentioned above, for the sale of its NuroPro diagnostic tests and the development of new drugs. For more info on PWRM.ob visit http://www.Power3Medical.com
Acacia Research Corporation (Nasdaq:ACTG) announced that its Lighting Ballast Control LLC subsidiary has entered into a settlement agreement with Koninklijke Philips Electronics N.V. covering patents relating to lighting ballasts.
ACTGs subsidiaries partner with inventors and patent owners, license the patents to corporate users, and share the revenue. Acacia Researchs subsidiaries control over 150 patent portfolios, covering technologies used in a wide variety of industries. For more info about Acacia Research is available at www.acaciatechnologies.com and www.acaciaresearch.com.
XenoPort, Inc. (Nasdaq:XNPT) announced that it will provide access via the World Wide Web to its presentation at the Wedbush Life Sciences Best Ideas Conference 2010. The live presentation will occur at 1:10 p.m. Pacific Time (4:10 p.m. Eastern Time) on Tuesday, August 3, 2010. A replay of the presentation will also be available.
To access the live presentation via the Web, please go to www.XenoPort.com.
XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the bodys natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. XenoPort is developing its lead product candidate in collaboration with Astellas Pharma Inc. and GlaxoSmithKline. XenoPorts product candidates are being studied for the potential treatment of moderate-to-severe primary restless legs syndrome, neuropathic pain, migraine headaches, gastroesophageal reflux disease, spasticity and Parkinsons disease.
To learn more about XenoPort, please visit the Web site at www.XenoPort.com.
For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer (http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)
